New Indian Health Magazine Features EECP® Therapy In Its Cover Story 

Vasomedical Applauds the International EECP® Therapist Association Call for International EECP® Therapy Week in Recognition of American Heart Month

Chapter Dedicated to EECP® Therapy in New Textbook on Coronary Artery Disease

Vasomedical Recorded Record Net Income of $2.47 Million for the Second Quarter of Fiscal 2012

More >>

January 23, 2012

Vasomedical Applauds the International EECP® Therapist Association Call for International EECP® Therapy Week in Recognition of American Heart Month

Company Encourages EECP® Therapy Centers to Participate and Offers Support

WESTBURY, N.Y. January 23, 2012 - Vasomedical, Inc. (“Vasomedical”) (OTC: VASO.PK), a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, announced its support for the International EECP® Therapists Association’s (IETA) announcement for the week of February 20 – 24, 2012 to be designated as the First Annual International EECP® Therapy Week in recognition of February as American Heart Month. The Company recognizes that the activities and events conducted by hundreds of centers internationally can potentially increase public awareness for EECP® therapy and have a positive effect on patient accessibility to the therapy.

The IETA requested today that EECP® centers worldwide make a unified statement in support of their EECP® therapy facilities by hosting events and activities during this week that will increase the awareness of patients and physicians about EECP® therapy. Suggested activities and events include local press releases and media contact, educational meetings presenting information on EECP® therapy and other topics of interest to cardiovascular patients,  physicians and other healthcare professionals, scheduled visits by local politicians, invitations for an open house, free blood pressure screening, blogs, videos, EECP® patient reunions and other suggestions that will make EECP® therapy and the dedicated physicians, therapists and centers that are committed to improving patient outcomes and their quality of life.

The Company encourages all Vasomedical EECP® providers worldwide to promote the recognition of American Heart Month by conducting activities that will provide information about heart disease and educate patients, physicians and other healthcare providers about the availability of EECP® therapy, an FDA cleared, Medicare covered non-invasive outpatient treatment for eliminating or reducing the symptoms of angina and heart failure. In support of these events, Vasomedical has offered to provide EECP® therapy centers with the latest tools available to plan events and activities which will provide information to patients and physicians how EECP® therapy can help them to lead fuller more productive lives.

EECP® therapy centers who wish to find out more about the planning tools and additional support mechanisms in place to assist them with International EECP® Therapy Week activities should visit the IETA web site at http://www.ietaonline.com  or the Vasomedical web site at www.vasomedical.com or http://www.eecp.com , respectively. They may also contact the company directly at marketing@vasomedical.com.    

Vasomedical, Inc. is engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of cardiovascular diseases and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. The Company also provides other noninvasive medical equipment including Holter monitors and ambulatory blood pressure monitors.

Vaso Diagnostics d/b/a VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc., is a professional sales representation organization offering vendors of medical devices an alternative third party sales channel. Through an agreement with GE Healthcare, it is currently engaged as an exclusive sales representative for certain GE Healthcare products.

Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.